Finafloxacin

Drug Profile

Finafloxacin

Alternative Names: AL-60371; BY-377; EXE 844; EXE 844b; Finafloxacin hydrochloride; Gastrochinolon; Gastroquinolone; Xtoro

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bayer
  • Developer Alcon; MerLion Pharmaceuticals
  • Class Antibacterials; Eye disorder therapies; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Otitis externa
  • Phase III Otitis media
  • Phase II Helicobacter infections; Pyelonephritis; Urinary tract infections
  • Phase I Bacterial infections; Respiratory tract infections

Most Recent Events

  • 01 Aug 2016 Alcon completes a phase III trial for Otitis media in USA (NCT02436304)
  • 30 Jun 2016 Alcon Research completes a phase III trial for Otitis media in USA (NCT02432105)
  • 30 May 2016 Alcon Research completes a phase I trial for Otitis media (In infants, in children) in USA (NCT02539654)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top